Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria T rns n - Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise - - Jan Van den Bossche Steps Down from Board After Si

Immunic, Inc. Strengthens Its Board of Directors

with the Appointment of Maria T rns n

Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise -

Jan Van den Bossche Steps Down from Board After Six Year Tenure -

July 6, 2022 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline

of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the appointment

of Maria T rns n, an industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets, to its

Board of Directors, effective July 5, 2022. The company also announced that Jan Van den Bossche has stepped down from the Board, effective

is a seasoned commercial executive, with 20 years of experience in sales and marketing as well as several operational and strategic leadership

roles in the U.S., EMEA, and other global territories," stated Duane Nash, M.D., J.D., MBA., Chairman of the Board of Directors

of Immunic. "Her expertise in scaling and optimizing commercial organizations to drive performance will be of tremendous value to

the Board, as we continue to advance our three development programs, most notably, the phase 3 ENSURE program of lead asset, vidofludimus

calcium, in patients with relapsing multiple sclerosis. I look forward to working with Maria and to leveraging her extensive knowledge

would also like to take this opportunity to thank Jan for his dedication to Immunic and his invaluable input as a member of the Board

of Directors over the last several years. We are very grateful for his contributions and offer him our best wishes in all future endeavors."

has served since July 2021 as Chief Commercial Officer at Passage Bio, where she is responsible for leading and building out the company's

commercial organization and strategy, including determining product positioning and paths to commercialization. From 2019 to 2021, Ms.

T rns n served as Senior Vice President and General Manager of Sarepta Therapeutics' U.S. Commercial organization, including

market access, trade & distribution, reimbursement, sales, patient services and marketing. From 2017 to 2019, she was Vice President,

Global Therapeutic Area Head of rare neurological, metabolic and endocrine diseases at Sanofi Genzyme, where she managed a $1.6 B portfolio

with five marketed and three pipeline products, and was commercial lead on multiple alliances. From 2011 to 2017, Ms. T rns n

held advancing commercialization roles in the endocrine and rare diseases groups at Shire, rising to the role of Vice President, Head

of Endocrine Rare Disease Sales, U.S. Commercial. Earlier in her career, she gained experience in global marketing and as a Product Specialist

at Merck KGaA and Eli Lilly, respectively.

earned a Master of Science (MSc) in International Business Administration from Lund University, Sweden.

(Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating

chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus

calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme

DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, and primary

sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR /ROR t, is targeted for development

in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. IMU-856, which targets the restoration of the intestinal

barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit:

Statement Regarding Forward-Looking Statements

This press release contains "forward-looking

statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities

Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy,

future operations, future financial position, future revenue, projected expenses, expected timing and results of clinical trials, prospects,

plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements

relating to Immunic's three development programs and the targeted diseases; the potential for Immunic's development programs

to safely and effectively target diseases; the nature, strategy and focus of the company and further updates with respect thereto; expectations

regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company.

Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking

statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's

current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those

projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and

uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and

business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements,

the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the

protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory

approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties

and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K

for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company's subsequent filings with

the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking

statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these

forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims

all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Head of Investor Relations and Communications

Rx Communications Group